Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise

There has been a collaborative global effort to construct novel therapeutic and prophylactic approaches to SARS-CoV-2 management. Although vaccine development is crucial, acute management of newly infected patients, especially those with severe acute respiratory distress syndrome, is a priority. Her...

Descripción completa

Detalles Bibliográficos
Autores principales: Nemunaitis, John, Stanbery, Laura, Senzer, Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249572/
http://dx.doi.org/10.2217/fvl-2020-0068
_version_ 1783538612978057216
author Nemunaitis, John
Stanbery, Laura
Senzer, Neil
author_facet Nemunaitis, John
Stanbery, Laura
Senzer, Neil
author_sort Nemunaitis, John
collection PubMed
description There has been a collaborative global effort to construct novel therapeutic and prophylactic approaches to SARS-CoV-2 management. Although vaccine development is crucial, acute management of newly infected patients, especially those with severe acute respiratory distress syndrome, is a priority. Herein we describe the rationale and potential of repurposing a dual plasmid, Vigil (pbi-shRNA(furin)-GM-CSF), now in Phase III cancer trials, for the treatment of and, in certain circumstances, enhancement of the immune response to SARS-CoV-2.
format Online
Article
Text
id pubmed-7249572
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Future Medicine Ltd
record_format MEDLINE/PubMed
spelling pubmed-72495722020-05-26 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise Nemunaitis, John Stanbery, Laura Senzer, Neil Future Virol Review There has been a collaborative global effort to construct novel therapeutic and prophylactic approaches to SARS-CoV-2 management. Although vaccine development is crucial, acute management of newly infected patients, especially those with severe acute respiratory distress syndrome, is a priority. Herein we describe the rationale and potential of repurposing a dual plasmid, Vigil (pbi-shRNA(furin)-GM-CSF), now in Phase III cancer trials, for the treatment of and, in certain circumstances, enhancement of the immune response to SARS-CoV-2. Future Medicine Ltd 2020-05-26 2020-04 /pmc/articles/PMC7249572/ http://dx.doi.org/10.2217/fvl-2020-0068 Text en © 2020 Future Medicine Ltd This work is licensed under the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/)
spellingShingle Review
Nemunaitis, John
Stanbery, Laura
Senzer, Neil
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise
title Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise
title_full Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise
title_fullStr Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise
title_full_unstemmed Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise
title_short Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise
title_sort severe acute respiratory syndrome coronavirus-2 (sars-cov-2) infection: let the virus be its own demise
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249572/
http://dx.doi.org/10.2217/fvl-2020-0068
work_keys_str_mv AT nemunaitisjohn severeacuterespiratorysyndromecoronavirus2sarscov2infectionletthevirusbeitsowndemise
AT stanberylaura severeacuterespiratorysyndromecoronavirus2sarscov2infectionletthevirusbeitsowndemise
AT senzerneil severeacuterespiratorysyndromecoronavirus2sarscov2infectionletthevirusbeitsowndemise

Ejemplares similares